Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

THOR IDE-studien (THOR)

2 november 2026 uppdaterad av: Philips Clinical & Medical Affairs Global

The goal of this clinical trial is to test the Thor system in adult (≥ 18 year old) patients with de novo (new, never treated) calcified lesions in infrainguinal (leg) arteries (peripheral artery disease or PAD).

The main question[s] it aims to answer are:

  • Is the Thor system safe in treating these lesions
  • Does the Thor system work to treat these lesions

Participants will:

  • Receive treatment with the Thor system
  • Have follow-up visits at Discharge, 30 days, 6 months, and 12 months

Studieöversikt

Detaljerad beskrivning

Up to 30 sites in the U.S. will be selected to do this study.

Patients with pain in their legs when walking and/or resting that is due to lack of blood flow to their legs may be able to join the study. To join the study patients must also have blockages in their leg arteries that meet the study criteria.

Before the Thor procedure, patients will have a screening visit that includes a review of their medical records, questions about their medical history and medications taken for blood thinning or circulation, a physical examination of their legs, a test to check the blood flow in their legs (by checking arm and leg blood pressures), blood tests, and a pregnancy test if they are a female able to have children. Patients will also answer questions about any trouble they have had with walking in the last week and their overall quality of life.

All patients in the study will have treatment with the Thor system. There is no "control group" (a group of patients that receives only standard treatment or receives no treatment at all) in this study. During the procedure, the doctor will take x-ray pictures of the leg arteries. They may also use other treatments such as angioplasty balloons, drug-coated balloons, stents, and filters that collect blood clots, if needed.

Patients treated with the Thor system will be watched until they are ready to go home or up to 24 hours after the procedure if they do not go home right away. Before they go home they will have a test to check the blood flow to their legs (by checking arm and leg blood pressures) and be checked for any adverse events.

Patients will return for visits at 30 days, 6 months, and 12 months after the Thor procedure. At these visits patients will be asked questions about their medical history and medications taken for blood thinning or circulation, have a physical examination of their legs, have a test to check the blood flow in their treated leg (by checking arm and leg blood pressures), have an ultrasound of their treated leg, and be checked for any adverse events. Patients will also answer questions about any trouble they have had with walking in the last week and their overall quality of life.

It will take up to 24 months (2 years) to enroll all of the patients in the study. Patients who join the study will be in the study for about 12 months (1 year) and will have all of the visits with their doctor that they would normally have for their PAD.

Studietyp

Interventionell

Inskrivning (Beräknad)

155

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

    • California
      • St. Helena, California, Förenta staterna, 94574
        • Indragen
        • St. Helena Hospital
    • Colorado
      • Aurora, Colorado, Förenta staterna, 80045
        • Rekrytering
        • Rocky Mountain Regional VA Medical Center
        • Huvudutredare:
          • Bilal Aijaz, MD
        • Kontakt:
        • Underutredare:
          • Stephen Waldo, MD
        • Kontakt:
    • Florida
      • Bradenton, Florida, Förenta staterna, 34205
      • Tallahassee, Florida, Förenta staterna, 32308
        • Rekrytering
        • Tallahassee Research Institute
        • Huvudutredare:
          • William Dixon
        • Kontakt:
        • Kontakt:
        • Underutredare:
          • John Katopodis
      • Winter Park, Florida, Förenta staterna, 32792
        • Rekrytering
        • Guardian Research Organization
        • Huvudutredare:
          • Ashish Gupta, MD
        • Kontakt:
        • Underutredare:
          • Sandeep Bajaj
        • Kontakt:
          • Tiffany King
    • Iowa
      • Davenport, Iowa, Förenta staterna, 52807
    • Louisiana
      • Houma, Louisiana, Förenta staterna, 70360
        • Rekrytering
        • Cardiovascular Institute of the South
        • Huvudutredare:
          • Craig Walker, MD
        • Underutredare:
          • Matthew Finn, MD
        • Underutredare:
          • Pradeep Nair, MD
        • Kontakt:
        • Kontakt:
        • Underutredare:
          • McCall Walker, MD
      • Lafayette, Louisiana, Förenta staterna, 70503
        • Rekrytering
        • Cardiovascular Institute of the South
        • Huvudutredare:
          • Ankur Lodha, MD
        • Kontakt:
        • Underutredare:
          • Amit Amin, MD
        • Underutredare:
          • David Tadin, MD
    • Maine
      • Portland, Maine, Förenta staterna, 04106
        • Rekrytering
        • The Vascular Care Group
        • Underutredare:
          • Todd Lancaster, MD
        • Underutredare:
          • Daniel Gorin, MD
        • Underutredare:
          • Christopher Kwolek, MD
        • Kontakt:
        • Huvudutredare:
          • Nathan Aranson, MD
    • Massachusetts
      • Fall River, Massachusetts, Förenta staterna, 02720
        • Rekrytering
        • Southcoast Hospitals/Charlton Memorial Hospital
        • Huvudutredare:
          • Richard Pin, MD
        • Kontakt:
        • Underutredare:
          • Mark Perry, MD
        • Underutredare:
          • Brandon Sumpio, MD
      • Leominster, Massachusetts, Förenta staterna, 04153
        • Aktiv, inte rekryterande
        • Vascular Breakthroughs
    • Michigan
      • Detroit, Michigan, Förenta staterna, 48202
        • Rekrytering
        • Henry Ford Hospital
        • Underutredare:
          • Pedro Villablanca, MD
        • Underutredare:
          • Khaldoon Alaswad, MD
        • Kontakt:
        • Underutredare:
          • Gerald Koenig, MD
        • Underutredare:
          • Vikas Aggarwal, MD
        • Underutredare:
          • Mohammad Alqarqaz, MD
        • Underutredare:
          • Herbert Aronow, MD
        • Huvudutredare:
          • Kyle Markel, MD
        • Kontakt:
      • Detroit, Michigan, Förenta staterna, 22201
        • Rekrytering
        • Henry Ford St John Hospital
        • Kontakt:
        • Huvudutredare:
          • Thomas Davis, Dr
        • Kontakt:
    • New Jersey
      • Browns Mills, New Jersey, Förenta staterna, 08015
        • Rekrytering
        • Deborah Heart and Lung Center
        • Huvudutredare:
          • Richard Kovach, MD
        • Kontakt:
        • Kontakt:
        • Underutredare:
          • Gregory Domer, MD
      • New Brunswick, New Jersey, Förenta staterna, 08901
        • Rekrytering
        • Heart and Vascular Institute of Central Jersey
        • Huvudutredare:
          • Ramzan Zakir, MD
        • Kontakt:
      • Vineland, New Jersey, Förenta staterna, 08360
        • Rekrytering
        • Atlantic Medical Imaging of New jersey
        • Huvudutredare:
          • Micah Watts, MD
        • Kontakt:
        • Kontakt:
        • Underutredare:
          • Nicholas Petruzzi, MD
        • Underutredare:
          • Ramkrishna Patel, MD
    • New York
      • New York, New York, Förenta staterna, 10029
        • Rekrytering
        • Mount Sinai Hospital
        • Huvudutredare:
          • Prakash Krishnan, MD
        • Underutredare:
          • David Song, MD
        • Kontakt:
        • Underutredare:
          • Vishal Kapur, MD
        • Underutredare:
          • Raman Sharma
        • Kontakt:
      • New York, New York, Förenta staterna, 10029
        • Rekrytering
        • New York Presbyterian Hospital/Columbia University Irving Medical Center
        • Kontakt:
        • Huvudutredare:
          • Virendra Patel, MD
        • Underutredare:
          • Thomas O'Donnell, MD
        • Underutredare:
          • Nicholas Morrissey
        • Underutredare:
          • Danielle Bajakian
        • Kontakt:
    • North Carolina
      • Cary, North Carolina, Förenta staterna, 27518
        • Rekrytering
        • Vascular Solutions of North Carolina
        • Kontakt:
        • Kontakt:
        • Huvudutredare:
          • Sid Rao, MD
    • Ohio
      • Fairborn, Ohio, Förenta staterna, 45324
        • Rekrytering
        • Premier Cardiovascular Institute
        • Huvudutredare:
          • Sagger Mawri, MD
        • Underutredare:
          • James Pan, MD
        • Kontakt:
        • Kontakt:
    • Oklahoma
      • Bartlesville, Oklahoma, Förenta staterna, 74006
        • Rekrytering
        • Ascension St. John
        • Kontakt:
        • Huvudutredare:
          • Anderson Merhle, MD
        • Underutredare:
          • Michael Megaly, MD
        • Kontakt:
          • Telefonnummer: 918.332.3616
    • Pennsylvania
      • Mechanicsburg, Pennsylvania, Förenta staterna, 17050
        • Rekrytering
        • UPMC
        • Kontakt:
        • Huvudutredare:
          • William Bachinsky, Dr
        • Kontakt:
      • Philadelphia, Pennsylvania, Förenta staterna, 19104
        • Rekrytering
        • Hospital of the University of Pennsylvania
        • Kontakt:
        • Huvudutredare:
          • Elizabeth Genovese, MD
        • Underutredare:
          • Shang Loh, MD
        • Underutredare:
          • Alexander Fairman, MD
        • Underutredare:
          • Douglas Troutman, MD
      • Wynnewood, Pennsylvania, Förenta staterna, 19096
        • Rekrytering
        • Lankenau Institute for Medical Research
        • Kontakt:
        • Huvudutredare:
          • Antonis Pratsos, MD
        • Underutredare:
          • Manju Jayanna, MD
        • Underutredare:
          • Sarang Mangalmurti, MD
        • Kontakt:
    • Rhode Island
      • Providence, Rhode Island, Förenta staterna, 02905
        • Rekrytering
        • The Miriam Hospital
        • Huvudutredare:
          • Peter Soukas, MD
        • Kontakt:
        • Underutredare:
          • Pieter de Klerk, MD
    • Tennessee
      • Chattanooga, Tennessee, Förenta staterna, 37421
        • Rekrytering
        • Vascular Institute of Chattanooga
        • Kontakt:
        • Underutredare:
          • William Harris, DO
        • Huvudutredare:
          • Chris LeSar, MD
    • Texas
      • Dallas, Texas, Förenta staterna, 75390
      • Plano, Texas, Förenta staterna, 75093
        • Rekrytering
        • Baylor, Scott & White, The Heart Hospital
        • Huvudutredare:
          • Sameh Sayfo, MD
        • Underutredare:
          • Chadi Dib, MD
        • Kontakt:
        • Kontakt:
        • Underutredare:
          • Tony Das, MD
    • Virginia
      • Norfolk, Virginia, Förenta staterna, 23507
        • Rekrytering
        • Sentara Health Research Center
        • Huvudutredare:
          • David Dexter, MD
        • Kontakt:
        • Underutredare:
          • Animesh Rathore, MD
        • Underutredare:
          • Priyam Vyas, MD

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Patient age is ≥18 years
  • Patient agrees to participate and to comply with the protocol by signing an IRB approved patient consent form
  • Patient is able to walk unassisted or with non-motorized assistive devices
  • Patient has PAD with documented Rutherford Class 2-4 of the target limb
  • Anticipated life expectancy >12 months, in the opinion of the investigator at the time of enrollment.

Angiographic Inclusion Criteria:

  • Patient has de novo atherosclerotic disease of the native SFA and/or the popliteal arteries
  • Target lesion has ≥70% diameter stenosis by investigator via visual assessment
  • Target lesion length ≤150mm. Total treatment zone may not exceed 150mm, and may include one or more lesions.
  • Chronic total occlusion lesion length is <100mm of the total ≤150mm target lesion
  • Minimum reference vessel diameter (RVD) 4.0mm by visual estimate
  • Target lesion crossed and intraluminal guidewire placement confirmed; successful crossing defined as tip of the guidewire distal to the target lesion in the absence of flow limiting dissections or perforations
  • At least one patent tibial vessel (defined as <50% stenosis) with runoff to the foot
  • Target lesion has moderate to severe calcification graded using the Peripheral Academic Research Consortium (PARC) criteria

Exclusion Criteria:

  • Patient has active infection requiring antibiotic therapy
  • Stenting planned within the target lesion
  • Known positive for COVID-19 within the last 2 weeks and actively symptomatic
  • Pregnant (positive pregnancy test) or currently breast feeding
  • Evidence of Acute Limb Ischemia in the target limb within 7 days prior to procedure
  • Cerebrovascular accident (CVA) <60 days prior to procedure
  • Myocardial infarction <60 days prior to procedure
  • History of unstable coronary artery disease or other uncontrollable comorbidity resulting in hospitalization within the last 60 days prior to baseline screening
  • Known contraindication to aspirin, or antiplatelet/anti-coagulant therapies required for procedure/follow-up
  • Known allergy to contrast media that cannot adequately be premedicated prior to study procedure
  • History of Thrombophilia, Heparin-induced Thrombocytopenia (HIT), or Heparin-induced Thrombotic Thrombocytopenia Syndrome (HITTS)
  • Serum creatinine ≥2.5mg/dL (unless dialysis-dependent) tested within 30 days prior to procedure
  • Planned lower limb major amputation (above the ankle)
  • Other surgical or endovascular procedure in the target limb that occurred within 14 days prior to index procedure or is planned on target limb for within 30 days following index procedure, with the exception of diagnostic angiography
  • Currently participating in any investigational device or drug clinical trial that, in the opinion of the investigator, will interfere with the conduct of the current study
  • The use of specialty balloons, re-entry or additional atherectomy devices is required for treatment of the target lesion.

Angiographic Exclusion Criteria:

  • Subject has significant stenosis (>50% stenosis) or occlusion of inflow tract before target treatment zone (e.g. iliac or common femoral) not successfully treated.
  • Subject requires treatment of a peripheral lesion on the ipsilateral limb distal to the target site at the time of the index procedure.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Thor Treatment

Treatment with the Thor system

Treatment of de novo calcified lesions with laser atherectomy and calcium modification using the Thor system

Andra namn:
  • Thor kalcium modifiering

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Freedom from Major Adverse Events (MAEs)
Tidsram: 30 Days

Defined as freedom from MAEs including all-cause mortality, clinically driven target lesion revascularization (CD-TLR), unplanned target limb major amputation, perforations, flow-limiting dissections, and symptomatic distal embolizations that require an intervention to resolve

30 Days
Procedural Success
Tidsram: At completion of the procedure

Defined as residual diameter stenosis ≤50% at the end of the procedure as determined by angiographic core lab

At completion of the procedure

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Target lesion patency, 30 days
Tidsram: 30 days

Defined as freedom from CD-TLR and freedom from ≥50% restenosis as determined by duplex ultrasound (DUS) or angiogram

30 days
Target lesion patency, 6 months
Tidsram: 6 months

Defined as freedom from CD-TLR and freedom from ≥50% restenosis as determined by duplex ultrasound (DUS) or angiogram

6 months
Target lesion patency, 12 months
Tidsram: 12 months

Defined as freedom from CD-TLR and freedom from ≥50% restenosis as determined by duplex ultrasound (DUS) or angiogram

12 months
Clinically-driven target lesion revascularization
Tidsram: Through 12 months

Defined as repeat revascularization procedure of the target lesion if PSVR is ≥2.5 by DUS or if angiography shows a percent diameter stenosis >50% and there are worsening clinical symptoms, worsening Rutherford Clinical Category or ABI that is clearly referable to the target lesion.

Through 12 months
Technical success
Tidsram: Peri-procedural

Defined as the ability to deliver the Thor system and achieve residual diameter stenosis ≤50% after treatment with Thor and prior to adjunctive PTA, as confirmed by independent core laboratory assessments of angiographic images

Peri-procedural
Frequency of peri-procedural adverse events
Tidsram: Within 24 hours of the procedure

Defined as frequency of adverse events related to the investigational device (Thor system)

Within 24 hours of the procedure
Adjunctive devices used with the Thor system
Tidsram: Peri-procedural

Defined as the use of other devices including angioplasty balloons, drug coated balloons, bailout stents, embolic filters

Peri-procedural
Target Limb Ankle-Brachial Index (ABI) change, Discharge
Tidsram: Discharge or up to 24 hours after the procedure

Defined as the change in blood pressure in the upper limb (arm) and lower limb (leg or toes) at discharge compared to the baseline (Screening) value

Discharge or up to 24 hours after the procedure
Target Limb Ankle-Brachial Index (ABI) change, 30 days
Tidsram: 30 days

Defined as the change in blood pressure in the upper limb (arm) and lower limb (leg or toes) at 30 days compared to the baseline (Screening) value

30 days
Target Limb Ankle-Brachial Index (ABI) change, 6 months
Tidsram: 6 months

Defined as the change in blood pressure in the upper limb (arm) and lower limb (leg or toes) at 6 months compared to the baseline (Screening) value

6 months
Target Limb Ankle-Brachial Index (ABI) change, 12 months
Tidsram: 12 months

Defined as the change in blood pressure in the upper limb (arm) and lower limb (leg or toes) at 12 months compared to the baseline (Screening) value

12 months
Rutherford Classification change, 30 days
Tidsram: 30 days

Defined as the change in Rutherford classification at 30 days compared to the baseline (Screening) value. Rutherford Classification is a staging system to describe reduced blood flow in the lower limb. Rutherford Classifications values range from the least severe (asymptomatic) which is scored a 0 to the most severe (ulceration or gangrene) which is scored a 6.

30 days
Rutherford Classification change, 6 months
Tidsram: 6 months

Defined as the change in Rutherford classification at 6 months compared to the baseline (Screening) value. Rutherford Classification is a staging system to describe reduced blood flow in the lower limb. Rutherford Classifications values range from the least severe (asymptomatic) which is scored a 0 to the most severe (ulceration or gangrene) which is scored a 6.

6 months
Rutherford Classification change, 12 months
Tidsram: 12 months

Defined as the change in Rutherford classification at 12 months compared to the baseline (Screening) value. Rutherford Classification is a staging system to describe reduced blood flow in the lower limb. Rutherford Classifications values range from the least severe (asymptomatic) which is scored a 0 to the most severe (ulceration or gangrene) which is scored a 6.

12 months
Freedom from Major Adverse Events (MAEs)
Tidsram: Through 12 months

Defined as freedom from MAEs including all-cause mortality, clinically driven target lesion revascularization (CD-TLR), unplanned target limb major amputation, and perforations, flow-limiting dissections, and symptomatic distal embolizations that require an intervention to resolve

Through 12 months
Change in Short Form Health Survey (SF-36) score, 30 days
Tidsram: 30 days

Defined as the change in SF-36 score at 30 days compared to the baseline (Screening) value. The SF-36 is a patient-reported survey of patient health. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

30 days
Change in Short Form Health Survey (SF-36) score, 6 months
Tidsram: 6 months

Defined as the change in SF-36 score at 6 months compared to the baseline (Screening) value. The SF-36 is a patient-reported survey of patient health. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

6 months
Change in Short Form Health Survey (SF-36) score, 12 months
Tidsram: 12 months

Defined as the change in SF-36 score at 12 months compared to the baseline (Screening) value. The SF-36 is a patient-reported survey of patient health. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

12 months
Change in Walking Impairment Questionnaire (WIQ) score, 30 days
Tidsram: 30 days

Defined as the change in WIQ score at 30 days compared to the baseline (Screening) value. The WIQ measures self-reported walking impairment, walking distance, walking speed, and stair-climbing ability. In the WIQ there are 21 questions to rate the degree of difficulty with the walking and stair climbing elements. The response for each question is on a 0 to 4 scale, where 0 represents the inability to walk or climb stairs, and 4 represents no difficulty.

30 days
Change in Walking Impairment Questionnaire (WIQ) score, 6 months
Tidsram: 6 months

Defined as the change in WIQ score at 6 months compared to the baseline (Screening) value. The WIQ measures self-reported walking impairment, walking distance, walking speed, and stair-climbing ability. In the WIQ there are 21 questions to rate the degree of difficulty with the walking and stair climbing elements. The response for each question is on a 0 to 4 scale, where 0 represents the inability to walk or climb stairs, and 4 represents no difficulty.

6 months
Change in Walking Impairment Questionnaire (WIQ) score, 12 months
Tidsram: 12 months

Defined as the change in WIQ score at 12 months compared to the baseline (Screening) value. The WIQ measures self-reported walking impairment, walking distance, walking speed, and stair-climbing ability. In the WIQ there are 21 questions to rate the degree of difficulty with the walking and stair climbing elements. The response for each question is on a 0 to 4 scale, where 0 represents the inability to walk or climb stairs, and 4 represents no difficulty.

12 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Samarbetspartners

Utredare

  • Huvudutredare: Elizabeth Genovese, MD, University of Pennsylvania
  • Huvudutredare: Pradeep Nair, MD, Cardiovascular Institute of the South (CIS)

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

29 oktober 2024

Primärt slutförande (Beräknad)

1 december 2026

Avslutad studie (Beräknad)

1 december 2027

Studieregistreringsdatum

Först inskickad

7 juni 2023

Först inskickad som uppfyllde QC-kriterierna

14 juni 2023

Första postat (Faktisk)

23 juni 2023

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

5 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

2 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Ja

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera